Literature DB >> 12718764

Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector.

Andrei N Varnavski1, Katia Schlienger, Jeffrey M Bergelson, Guang-Ping Gao, James M Wilson.   

Abstract

Using recombinant adenoviruses (Ads) to target host dendritic cells (DCs) presents an attractive prospect for immunization. The efficacy of commonly used human Ad-derived gene transfer vectors for antigen delivery in humans is often compromised by preexisting anti-Ad immunity, acquired by the majority of human population as a result of frequent naturally occurring virus infections. As an alternative vector we propose chimpanzee-derived recombinant adenoviruses, which are poorly neutralized by human sera. In the present study we examine the ability of one such vector, AdC68, to transduce and activate human monocyte-derived DCs in culture. We found that AdC68 could efficiently transduce both immature and mature DCs at levels similar to those by the human serotype 5 Ad recombinant. Exposure of immature DCs to AdC68 did not alter the expression of activation and maturation marker molecules on the cell surface. Nevertheless, the transduction induced DCs to secrete interferon alpha and interleukin (IL)-6, but not IL-12 or tumor necrosis factor alpha. In addition, AdC68-transduced immature DCs could stimulate proliferation of autologous T lymphocytes. This is the first report describing a chimpanzee-derived recombinant Ad as a vector for transduction of human DCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12718764     DOI: 10.1089/104303403764539323

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

Review 1.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

2.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

3.  Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.

Authors:  Anja Krause; Wen Zhu Whu; Yaqin Xu; Ju Joh; Ronald G Crystal; Stefan Worgall
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

4.  Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza.

Authors:  Jianping Lin; Suryanarayan Somanathan; Soumitra Roy; Roberto Calcedo; James M Wilson
Journal:  Vaccine       Date:  2010-06-29       Impact factor: 3.641

5.  Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.

Authors:  Helen Cho; Joe Binder; Risini Weeratna; Michael Dermyer; Stanley Dai; Antionio Boccia; Wei Li; Shangjin Li; Karin Jooss; James Merson; Robert E Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2022-07-13       Impact factor: 6.630

6.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 7.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

Review 8.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

9.  Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.

Authors:  Nia Tatsis; Marcio O Lasaro; Shih-Wen Lin; Larissa H Haut; Zhi Q Xiang; Dongming Zhou; Lauren Dimenna; Hua Li; Ang Bian; Sarah Abdulla; Yan Li; Wynetta Giles-Davis; Jessica Engram; Sarah J Ratcliffe; Guido Silvestri; Hildegund C Ertl; Michael R Betts
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

10.  Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.

Authors:  T Osada; X Y Yang; Z C Hartman; O Glass; B L Hodges; D Niedzwiecki; M A Morse; H K Lyerly; A Amalfitano; T M Clay
Journal:  Cancer Gene Ther       Date:  2009-02-20       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.